

Laura E Kilpatrick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/637149/publications.pdf>

Version: 2024-02-01

19
papers

867
citations

687363

13
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

1118
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1264.	4.1	293
2	NanoBRET Approaches to Study Ligand Binding to GPCRs and RTKs. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 136-147.	8.7	81
3	Binding kinetics of ligands acting at GPCRs. <i>Molecular and Cellular Endocrinology</i> , 2019, 485, 9-19.	3.2	79
4	Probing the pharmacology of G protein-coupled receptors with fluorescent ligands. <i>Neuropharmacology</i> , 2015, 98, 48-57.	4.1	65
5	Studying GPCR Pharmacology in Membrane Microdomains: Fluorescence Correlation Spectroscopy Comes of Age. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 158-174.	8.7	54
6	Kinetic analysis of antagonist-occupied adenosine A ₃ receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism. <i>FASEB Journal</i> , 2014, 28, 4211-4222.	0.5	49
7	Real-time analysis of the binding of fluorescent VEGF 165 a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes. <i>Biochemical Pharmacology</i> , 2017, 136, 62-75.	4.4	46
8	Transactivation of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs): Recent insights using luminescence and fluorescence technologies. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 16, 102-112.	1.4	38
9	Real-Time Ligand Binding of Fluorescent VEGF-A Isoforms that Discriminate between VEGFR2 and NRP1 in Living Cells. <i>Cell Chemical Biology</i> , 2018, 25, 1208-1218.e5.	5.2	32
10	Complex Formation between VEGFR2 and the β 2-Adrenoceptor. <i>Cell Chemical Biology</i> , 2019, 26, 830-841.e9.	5.2	27
11	Subtype-Selective Fluorescent Ligands as Pharmacological Research Tools for the Human Adenosine A _{2A} Receptor. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2656-2672.	6.4	25
12	A G Protein-Coupled Receptor Dimer Imaging Assay Reveals Selectively Modified Pharmacology of Neuropeptide Y ₁ /Y ₅ Receptor Heterodimers. <i>Molecular Pharmacology</i> , 2015, 87, 718-732.	2.3	20
13	The use of fluorescence correlation spectroscopy to characterize the molecular mobility of fluorescently labelled G protein-coupled receptors. <i>Biochemical Society Transactions</i> , 2016, 44, 624-629.	3.4	14
14	Use of NanoBiT and NanoBRET to monitor fluorescent VEGF binding kinetics to VEGFR2/NRP1 heteromeric complexes in living cells. <i>British Journal of Pharmacology</i> , 2021, 178, 2393-2411.	5.4	13
15	Comparison of the ligand-binding properties of fluorescent VEGF isoforms to VEGF receptor 2 in living cells and membrane preparations using NanoBRET. <i>British Journal of Pharmacology</i> , 2019, 176, 3220-3235.	5.4	11
16	Detection of genome-edited and endogenously expressed G protein-coupled receptors. <i>FEBS Journal</i> , 2021, 288, 2585-2601.	4.7	10
17	The use of fluorescence correlation spectroscopy to characterise the molecular mobility of G protein-coupled receptors in membrane microdomains: an update. <i>Biochemical Society Transactions</i> , 2021, 49, 1547-1554.	3.4	4
18	Synthesis of novel (benzimidazolyl)isoquinolinols and evaluation as adenosine A ₁ receptor tools. <i>RSC Advances</i> , 2018, 8, 16362-16369.	3.6	3

#	ARTICLE	IF	CITATIONS
19	Efficient G protein coupling is not required for agonist-mediated internalization and membrane reorganization of the adenosine A ₃ receptor. FASEB Journal, 2021, 35, e21211.	0.5	3